Spruce Biosciences raises $53.6M in private placement of common stock and warrants

SPRUCE BIOSCIENCES, INC.

Issued 16.1M shares, 0.8M pre-funded warrants, and 12.7M standard warrants; purchase price $3.17 per share.
Gross proceeds of ~$53.6M; standard warrants exercisable at $3.96 per share for 5 years.
Closing expected on or before February 17, 2023; SVB Securities is placement agent (5% fee).
Company must file registration statement within 30 days of closing to register resale of securities.
Purchasers include Abingworth, HealthCap, Novo Holdings, RiverVest, and Rock Springs.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $53.6 million (effective 2023-02-08).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $53.6 million
Effective: 2023-02-08

Exact text from the filing

On February 8, 2023, Spruce Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue (i) 16,116,000 shares of the Company’s common stock (“Common Stock”), (ii) pre-funded warrants to purchase 800,000 shares of Common Stock (the “Pre-Funded Warrants”) to a Purchaser and (iii) 12,687,000 warrants to purchase Common Stock (the “Standard Warrants” and together with the Pre-Funded Warrants, the “Warrants”) in a private placement transaction (the “Private Placement”).

View on SEC.gov

76 material agreements filed in the last 30 days. Browse all material agreements →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-002369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.